Background. Mutant mouse models suggest that the chloride channel ClC-2 has
Introduction
ClC-2 is a chloride channel that is almost ubiquitously expressed in the human body (Planells-Cases & Jentsch, 2009) . It is present in plasma membranes and is activated by hyperpolarisation, acidic extracellular pH, and osmotic cell swelling (Planells-Cases & Jentsch, 2009; Thiemann et al., 1992; Grunder et al., 1992; Jordt & Jentsch, 1997) . Its functions in human physiology are a matter of debate. Roles in gastric acid secretion, lung development and function, and nephronogenesis have been suggested, but not confirmed (Planells-Cases & Jentsch, 2009; Bosl et al., 2001 ). Information about the localisation of ClC-2 within the brain comes from rodent studies, which have detected ClC-2 in oligodendrocytes, astrocytes (especially in endfeet), and pyramidal and nonpyramidal neurons in the hippocampus (Blanz et al., 2007; Sik et al., 2000) .
Evidence suggests that ClC-2 modulates postsynaptic responses to GABA by affecting intracellular chloride concentration in neurons (Smith et al., 1995) and that ClC-2 regulates neuronal excitability (Rinke et al., 2010; Ratte & Prescott, 2011) , but the physiological relevance of these findings has not been confirmed.
Physiological roles of proteins can be gleaned from diseases caused by mutations in their genes. No human disease has been unequivocally related to mutations in CLCN2, the gene encoding ClC-2. Heterozygous mutations in CLCN2 were described as a cause of idiopathic generalised epilepsies (D'Agostino et al., 2004; Stogmann et al., 2006; Everett et al., 2007; Combi et al., 2009; Kleefuss-Lie et al., 2009; Haug et al., 2009 ), but this finding was later refuted (Planells-Cases & Jentsch, 2009; Niemeyer et al., 2010) and the original paper was retracted (Haug et al., 2009) . Because mutant mice without functional ClC-2 have a leukoencephalopathy with intramyelinic oedema (Bosl et al., 2001; Blanz et al., 2007; Edwards et al., 2010) , ClC-2 was proposed to have a role in brain ion and water homoeostasis (Bosl et al., 2001; Blanz et al., 2007) ; however, this hypothesis has not been confirmed in human beings. A known human disorder characterised by intramyelinic oedema is megalencephalic leukoencephalopathy with subcortical cysts (van der Knaap et al., 1995 Knaap et al., , 1996 . Mutations in MLC1 have been identified in 75% of patients with this disorder (Leegwater et al., 2001; van der Knaap et al., 2010) . No mutations in CLCN2 were reported in the patients without MLC1 mutations (Sheper et al., 2010) . Recently, mutations in HEPACAM (also called GLIALCAM), which encodes the glial cell adhesion molecule (GlialCAM) -a putative auxiliary subunit of both ClC-2 and MLC1 (LopezHernandez et al., 2011; Jeworutzki et al., 2012) -were identified in patients without MLC1 mutations (Lopez-Hernandez et al., 2011) .
We aimed to study patients with leukoencephalopathies of unknown origin to define novel disorders characterised by distinct patterns of MRI abnormalities (van der Knaap et al., 1999) and identify the mutated genes. We were specifically interested in leukoencephalopathies with MRI evidence of intramyelinic oedema. When we identified CLCN2 mutations in a group of such patients, we sought further evidence for ClC-2's function in human physiology.
Methods

Study design and patients
In this observational analytical study, we used MRI criteria to recruit adult and paediatric patients from the Amsterdam and Paris leukoencephalopathy databases containing MRI images of patients with leukoencephalopathies of unknown origin submitted from all over the world. Patients with prominent signal abnormalities in the middle cerebellar peduncles, midbrain cerebral peduncles, and posterior limbs of the internal capsules were included in the study.
We studied the MRI results of each patient and scored the appearance and distribution of signal abnormalities. We assessed apparent diffusion coefficient (ADC) values in areas of abnormal signal. Signal intensity on T2-weighted and T1-weighted images and ADC values provide information on tissue microstructure.
High ADC values indicate large water spaces; low ADC values indicate small water spaces. Because the study was multi-institutional, MRIs were done with different pulse sequences on machines from different vendors. Therefore, we used a robust cutoff ADC value of 60×10−⁵ mm²/s, below which the diffusion was considered to be restricted. Subtle diffusion restriction could, therefore, have been missed.
We obtained approval from the institutional review boards of the participating centres in Paris and Amsterdam (Hôpital Pitié-Salpêtrière and VU University Medical Centre) and informed consent from patients and their families.
Procedures
Exome sequencing was undertaken in the three patients with adult-onset disease under the assumption that these patients had one disease with autosomal recessive inheritance. In patient 3, who has consanguineous parents, we identified homozygous regions (appendix), in which we searched for homozygous mutations.
One paediatric patient came from a family with X-linked disease inheritance, and this family participated in another exome sequencing study focused on X-linked disorders. We then used Sanger sequencing to sequence the CLCN2 gene in both the adult and paediatric patients; GJB1, which encodes the gap junction beta-1 protein (also known as connexin 32), was sequenced in the male patient without CLCN2 mutations (appendix).
CLCN2 mRNA was quantified in fibroblasts of adult patients with CLCN2 mutations. Transient transfections of wild-type or mutant ClC-2-V5-His6 expression plasmids in COS7 cells were used to study the functional effects of CLCN2 mutations (appendix).
To define which cell types express ClC-2 in healthy mature human brain, we examined the posterior limb of the internal capsule, frontal white matter, frontal cortex, and ependyma with fluorescence immunohistochemistry of tissue obtained at autopsy from nine patients aged 1-75 years (appendix) who succumbed to heart disease or extracerebral neoplasm. None of the patients had neurological symptoms and neuropathological examination showed no abnormalities.
Immunohistochemistry (appendix) was done on frozen tissue using antibodies against ClC-2, GlialCAM, MLC1, glial fibrillary acidic protein (GFAP; an astrocyte marker), oligodendrocyte transcription factor-2 (OLIG2; an oligodendrocyte marker), neuronal nuclear antigen (NeuN; a neuronal marker, also known as RBFOX3), platelet endothelial cell adhesion molecule-1 (PECAM1; an endothelial marker, also known as CD31), and phosphorylated and non-phosphorylated neurofilament H (SMI31 and SMI32, respectively; axonal markers). The anti-ClC-2 antibodies were validated for specificity (appendix). All sections were counterstained with DAPI (4',6-diamidino-2-phenylindole; nuclear staining).
Electron microscopy was done on tissue from the posterior limb of the internal capsule (appendix). Sections were incubated with ClC-2, GlialCAM, and MLC1
antibodies.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Seven patients met our inclusion criteria, three with adult-onset disease and four with childhood-onset disease. The three patients with adult-onset disease were unrelated (patients 1-3; table 1). They had mild cerebellar ataxia and a variable combination of chorioretinopathy with visual field defects, optic neuropathy, and headaches. One patient had a schizophrenia-like disorder. The three patients with childhood-onset disease and CLCN2 mutations (patients 4-6) had mild cerebellar ataxia and a variable combination of mild spasticity, visual field defects, learning disabilities, and headaches (table 1) .
The patient with X-linked disease (patient 7; table 1) presented with nystagmus at 12 months. He developed incapacitating cerebellar ataxia and spasticity. Clinical evidence of peripheral nerve involvement was absent, although recent neurophysiological investigations revealed mild motor neuropathy. Affected male family members had the same clinical and MRI findings. Carrier females had no abnormalities.
All patients had prominent signal abnormalities and decreased ADC values in the posterior limbs of the internal capsules, cerebral peduncles in the midbrain, pyramidal tracts in the pons, and middle cerebellar peduncles ( fig. 1; appendix) . All patients with adult-onset disease had additional signal abnormalities in specific brainstem tracts and the cerebellar white matter (appendix). Cerebral hemispheric white matter abnormalities were mild and non-specific. In one patient (patient 1), low to borderline-low ADC values were also found in cerebral white matter areas (appendix).
In the paediatric patients, the same additional signal abnormalities in specific brainstem tracts and cerebellum were noted. Additionally, they had diffuse mild signal abnormality of the brain white matter, which was hyperintense relative to grey matter on T2-weighted and T1-weighted images ( fig. 1 ). Low to borderline-low ADC values were present in the cerebral and cerebellar hemispheric white matter and corpus callosum. The signal behaviour of the white matter on T1-weighted and T2-weighted images would typically suggest hypomyelination (Schiffmann & van der Knaap, 2009 ), but hypomyelination is associated with increased size of water spaces and therefore increased ADC values (Dreha-Kulaczewski et al., 2012) . The low white matter ADC suggests myelin microvacuolation instead of hypo myelination (Patay, 2005) . Increased intramyelinic water accounts for the mild T2-signal changes.
As a result of exome sequencing and homozygosity mapping in patient 3, we identified ten homozygous single nucleotide substitutions and two homozygous insertion-deletions with a possible effect on gene or protein function that were absent from control databases (appendix). One was a homozygous in-frame deletion (p.Leu144_Ile145del) in CLCN2. Analysis of exome data in the other adult patients revealed the same homozygous non-sense mutation (p.Trp570X) in CLCN2 (table 2; appendix). CLCN2 was the only gene that contained at least one homozygous or at least two heterozygous, possibly deleterious variants in all three patients that were absent from exome data from individuals with other diseases analysed at the same time (appendix).
Analysis of the coding sequence of CLCN2 by Sanger sequencing in the paediatric patients identified homozygous or compound-heterozygous CLCN2 mutations in three patients (table 2; appendix). All mutations were predicted to be pathogenic and none was present in healthy controls of the same origin or in the International Hapmap Project and the 1000 Genomes Project databases (appendix).
Sequencing of the exome of the paediatric patient without CLCN2 mutations who had an X-linked family history revealed a novel missense mutation (p.Pro174Ser) in GJB1 (table 2; appendix). This mutation was confirmed in his mother and in one living similarly affected male family member.
Quantification of the CLCN2 mRNA in fibroblasts from patients and controls by real-time quantitative PCR showed that the mRNA with the p.Trp570X mutation was substantially downregulated compared with that of controls, by contrast with the mRNA with p.Leu144_Ile145del (appendix). Treatment with emetine, an inhibitor of non-sense mediated decay, rescued the mRNA expression, suggesting that p.Trp570X leads to degradation of the mutant mRNA, although a substantial fraction of the mRNA subsists. We could not confirm the presence of the truncated protein because expression of ClC-2 was undetectable in fibroblasts. Transient expression of the protein with the p.Trp570X mutation in COS7 cells showed that the truncated protein, if expressed, has an aberrant localisation restricted to the Golgi apparatus (appendix).
The p.Leu144_Ile145del and p.Ala500Val mutations are thought to affect conserved hydrophobic aminoacids located in transmembrane domains of ClC-2, possibly leading to protein misfolding or misinsertion in the membrane. To test this hypothesis, we compared the expression and subcellular localisation of V5-His6-tagged ClC-2 with the p.Leu144_Ile145del or p.Ala500Val mutation to those of the wild-type protein in COS7 cells. Localisation of the p.Leu144_Ile145del ClC-2 and p.Ala500Val ClC-2 proteins was restricted to the endoplasmic reticulum, whereas wild-type ClC-2 was present in different subcellular compartments including the plasma membrane ( fig. 2A) . Additionally, the amount of both mutated ClC-2 proteins transiently expressed in COS7 cells was lower than the amount of wild-type ClC-2 ( fig. 2B ) and the mutated proteins hardly reached the plasma membrane ( fig. 2C,D) . These findings suggest that p.Leu144_Ile145del ClC-2 and p.Ala500Val ClC-2 are trapped and degraded in the endoplasmic reticulum.
Altogether, these results suggest that all mutations identified in the patients led to a complete or at least partial loss of function of the ClC-2 channel by different mechanisms.
Immunohistochemistry show high signal in the midbrain cerebral peduncles (arrow in E), posterior limbs of the internal capsules (arrow in F), and to a lesser extent the posterior subcortical cerebral white matter (compare hyperintense posterior white matter to normal anterior white matter in E and F), suggesting restricted diffusion, confirmed by low ADC values on the ADC maps (low signal in G and H, arrows). MRI in patient 4 at the age of 14 years (I-P) shows diffuse mild T2-hyperintensity (I-K) and T1-hyperintensity (L) of all white matter structures. Prominent T2-hyperintensity is seen in the basis pontis (I), middle cerebellar peduncles (I), midbrain cerebral peduncles (J), and posterior limbs of the internal capsules (K). Diffusion-weighted images (M, N) show increased signal in virtually all white matter, especially the midbrain cerebral peduncles (arrow in M) and posterior limbs of the internal capsules (arrow in N), suggesting restricted diffusion, confirmed by low ADC values on the ADC maps (arrows in O and P). MRI in patient 7 at the age of 14 years (Q-X) shows diffuse mild T2-hyperintensity (Q-S) and T1-hyperintensity (T) of all white matter structures. Prominent T2-hyperintensity is seen in the middle cerebellar peduncles (Q), midbrain cerebral peduncles (R), and posterior limbs of the internal capsules (S). Diffusion-weighted images (U, V) show mildly increased signal in almost all white matter, especially the midbrain cerebral peduncles (arrow in U) and posterior limbs of the internal capsules (arrow in V), suggesting restricted diffusion, confirmed by low ADC values on the ADC maps (arrows in W and X). immunoreactivity overlapped consistently and extended further distally than ClC-2 into astrocytic endfeet approaching the basal lamina ( fig. 3C ; appendix). A more discrete, punctate ClC-2 immunoreactivity was visible intermittently along axons (appendix). We detected many ClC-2-positive and GFAP-negative cells with the morphology of oligodendrocytes. In the frontal cortex, ClC-2 expression was detected only in scattered protoplasmic astrocytes around blood vessels and in astrocytes that are part of the glia limitans ( fig. 3D ; appendix). In these locations, ClC-2 astrocytes coexpressed GlialCAM ( fig. 3E ; appendix) and MLC1 (appendix). ClC-2 expression was also detected in the ependymal lining, again overlapping with GlialCAM ( fig. 3F ; appendix) and MLC1 (appendix). No ClC-2-positive expression was noted in neuronal perikarya ( fig. 3G ).
Electron microscopy confirmed that ClC-2 was abundantly present in white matter 
Discussion
We showed that autosomal recessive loss-of-function mutations in CLCN2 cause a leukoencephalopathy with MRI evidence of myelin microvacuolation. These findings are similar to those in ClC-2-deficient mice and are in line with the notion that ClC-2 in the brain is involved in ion and water homoeostasis (panel) (Bosl et al., 2001; Blanz et al., 2007) .
Our observations do not support the hypothesis that loss-of-function mutations in CLCN2 confer an increased risk of epilepsy. None of the six patients with homozygous or compound heterozygous mutations in CLCN2 had epilepsy or a family history of epilepsy, suggesting that partial or complete ClC-2 loss of function per se is insufficient to cause epilepsy.
The disease associated with CLCN2 mutations is variable in age of onset and clinical presentation. Mild cerebellar ataxia is the most consistent finding.
Retinopathy, as reported in the ClC-2-deficient mice, was detected in only some of the patients, although the visual field defects in absence of other ophthalmological Quantification of wild-type and mutant ClC-2 proteins present in whole lysates and in plasma membranes shows that, overall, mutant ClC-2 proteins are not as frequently expressed as wild-type ClC-2, suggesting that they are misfolded and instable. By contrast with the wild-type form, both mutants are retained in the endoplasmic reticulum where they are probably degraded and hardly reach the plasma membrane. The values, obtained from at least three different experiments, were compared with the Mann-Whitney test. *p<0.05. **p<0.01. ***p<0.001.
findings suggest that the other patients might have had a retinopathy that was too subtle to be picked up at funduscopy. ClC-2-deficient mice are sterile because of testicular degeneration; however, the only male patient with CLCN2 mutations (aged 15 years) did not yet show signs of testicular degeneration. Although the clinical presentation of the patients is non-specific and does not allow a diagnosis, MRI findings in these patients are highly specific and do allow a diagnosis. We have also analysed the CLCN2 gene in several other adult and paediatric patients who had similar MRI findings to those of study patients, but did not meet the MRI inclusion criteria, and we did not find CLCN2 mutations in any of them (data not shown).
The phenotypic variability reported in the patients might at least in part be related to the extent of ClC-2 loss of function. Both the mutational variation and functional analyses suggest loss of function of ClC-2, but some mutated proteins, in particular C-terminally truncated or missense mutants that reach the plasma membrane in substantial amounts, could possibly retain a partial function.
The present study adds to the growing insight into how the brain deals with the continuous shifts of ions and water related to action potentials. Brain white matter mainly consists of myelinated axons and its most important physiological function is impulse conduction. Action potentials are based on shifts in ions, which are obligatorily associated with osmotically driven shifts in water, needing rapid compensation. Any disturbance of the compensatory mechanisms might disrupt impulse transmission or lead to life-threatening changes in brain volume. Brain ion and water homoeostasis is complex and involves electrolytes and organic osmolytes, channels, and transporters, and coordinated processes such as regulatory volume decrease and increase to correct cell volume changes (Benfenati & Ferroni, 2010; . Astrocytes are central in this process.
They are the most abundant and best connected cell type of the so-called panglial syncytium, a vast network of astrocytes, oligodendrocytes, and ependymal cells interconnected by gap junctions. The panglial syncytium is essential for longdistance disposal of ions and water (Benfenati & Ferroni, 2010; .
Action potentials are associated with disposal of submyelinic and intramyelinic potassium . In myelinated axons, depolarisation is associated with influx of sodium at nodes of Ranvier; compensatory potassium efflux occurs in paranodal regions covered by myelin (appendix). Gap junctions help to transport potassium and osmotic water across myelin layers into astrocytes. Connexin 32 constitutes gap junctions in paranodal myelin; connexin 32 and connexin 47 constitute gap junctions between myelin and astrocytes. The astrocytic syncytium allows rapid dispersion of potassium and buffers the associated volume changes. This process of so-called potassium siphoning prevents action-potential-induced osmotic intramyelinic oedema . Disruptions of molecular components of these ion and water homoeostatic pathways are associated with intramyelinic oedema in human diseases and mutant mouse models (Blanz et al., 2007; Edwards et al., 2010; Neusch et al., 2001; Menichella et al., 2006) . No myelin vacuolation occurs in mouse models in the absence of action potentials (Blanz et al., 2007; Neusch et al., 2001) ,
showing that hindrance of compensation of action-potential-induced ion and water shifts is the main factor leading to osmotic intramyelinic oedema.
Insight into the mechanisms and molecular components of brain ion and water homoeostatic pathways is still incomplete. Our study provides evidence that ClC-2 is one of these molecular components. The first observation that supports a role of shows that all GFAP-positive astrocytes express ClC-2 (A). Note the long ClC-2-positive astrocytic processes extending parallel and perpendicular to the direction of the fibre bundle. ClC-2 shows a punctuate immunoreactivity, as expected for a membrane protein (inset in A). Colabelling of the same tissue for ClC-2 (green) and the vascular endothelial cell marker CD31 (also known as PECAM1; red) shows that expression of ClC-2 is enhanced in the astrocytes surrounding the blood vessels deep in the parenchyma (B) and the penetrating vessels at the surface of the brain (D). Note the many fine astrocytic processes running along the white matter capillary (B). Perivascular astrocytes (C), subpial astrocytes (E), and ependymal cells (F) coexpress GlialCAM (red) with ClC-2 (green), but GlialCAM immunoreactivity extends further into the astrocytic processes and endfeet (inset in C). Double staining of the frontal cortex for ClC-2 (green) and the neuronal marker NeuN (red) shows that, in this location,
ClC-2 immunoreactivity is restricted to perivascular astrocytes (G). No ClC-2 expression is seen in the NeuN-positive neuronal cells (inset in G). In all images the cell nuclei are stained with DAPI (4´,6-diamidino-2-phenylindole; blue). Original magnifications: (A) 100×, (B) 630×, (C-G) 200×, (insets) 400×.
Figure 4: Electron microscopy: ClC-2, GlialCAM, and MLC1 immunoreactivity in the healthy adult white matter. ClC-2 is expressed on astrocytic processes in between myelinated axons (A) and in contact with abaxonal myelin (inset in A). A similar localisation is observed for GlialCAM (C). Intense ClC-2 immunoreactivity is present in astrocytic endfeet surrounding blood vessels (B). Note the enhanced ClC-2 expression in the astrocyte-astrocyte contacts of the endfeet (B). At this site, GlialCAM (D) and MLC1 (E) are also expressed. Scale bars=1 μm. ast=astrocyte. bm=basement membrane.
m=myelin.
2002). We have no explanation for why the mutation detected in the family that we studied has a persistent effect on brain myelin, without any fluctuation, both
clinically and on serial MRI. The serious spasticity and cerebellar ataxia probably over shadow the neuropathy, which was only detected by neurophysiological studies after the GJB1 mutation had been identified. Other cases of X-linked Charcot-Marie-Tooth disease with persistent clinical signs of brain dysfunction and white matter disease on MRI have been reported, but diffusion findings were not mentioned (Siskind et al., 2009) . The third observation supporting the role of ClC-2 in brain ion and water homoeostasis is the ClC-2 membrane expression in the panglial syncytium, with enhanced expression around blood vessels, in the glia limitans, ependymal lining, and astrocyte-astrocyte contacts in the white matter.
The fourth observation is the finding that ClC-2 colocalises with MLC1 and GlialCAM in astrocytic endfeet at the perivascular basal lamina and glia limitans (Lopez-Hernandez et al., 2011; Jeworutzki et al., 2012; Boor et al., 2005) . As recently reviewed (van der , both GLIALCAM and MLC1 mutations cause megalencephalic leukoencephalopathy with subcortical cysts (Leegwater et al., 2001; Lopez-Hernandez et al., 2011) , a disease characterised by myelin vacuolation in the cerebral white matter, in which the corpus callosum, internal capsule, brainstem, and cerebellum are spared in comparison (van der Knaap et al., 1995 Knaap et al., & 1996 . MLC1 is involved in chloride currents necessary for the astrocytic regulatory volume decrease after cell swelling (Ridder et al., 2011) . GlialCAM is indispensable for correct localisation of MLC1 and ClC-2 (Lopez- Hernandez et al., 2011; Jeworutzki et al., 2012) . Results of our study suggest that ClC-2 is part of the same ion and water homoeostatic pathways as MLC1 and GlialCAM (appendix).
A limitation of our study is the rather small number of patients. The database on unclassified leukoencephalopathies in Amsterdam contains more than 3000
patients, but only a few patients fulfilled the MRI criteria. It could be that the ClC-2-related leukoencephalopathy is very rare, but we cannot exclude the possibility that the phenotypic variation is much wider and that we have not analysed a sufficient number of patients yet. Another issue is the specificity of the antibody against human ClC-2. To provide full proof, absence of all staining should be shown in brain tissue of a patient with two CLCN2 null mutations. This tissue is not available.
However, we did several experiments that support the specificity of the antibody and thus the validity of the immunohistochemical data (appendix).
Many questions remain. The exact role of ClC-2 in brain ion and water homoeostasis is unknown. Why defects in the same pathways cause different white matter disorders is unclear. ClC-2-related and connexin-32-related diseases preferentially affect white matter structures that are spared (relatively) by MLC1-related and GlialCAM-related disease. Although recessive mutations in MLC1 and GLIALCAM lead to diff use cerebral white matter oedema, sparing the corpus callosum, internal capsule, brainstem, and cerebellum, recessive mutations in CLCN2 and GJB1 preferentially cause white matter oedema of the internal capsule, brainstem structures, and cerebellum. Another intriguing question concerns the size of the myelin vacuoles. In MLC, ADC values in the affected white matter are highly increased (van der Voorn et al., 2006) , suggesting large vacuoles and increased extracellular spaces, as confirmed by electron microscopy (van der Knaap et al., 1996) . In ClC-2-related and connexin-32-related disease, ADC values in affected white matter are low, suggesting small intramyelinic vacuoles and extracellular spaces. Although GlialCAM is supposed to be a chaperone for both MLC1 and ClC-2 (Lopez-Hernandez et al., 2011; Jeworutzki et al., 2012) , recessive GLIALCAM mutations lead to a disease that is indistinguishable from the disease caused by MLC1 mutations and does not share the MRI features of the disease caused by CLCN2 mutations (Lopez-Hernandez et al., 2011) . We noted that GlialCAM and MLC1 share restricted localisation in distal astrocytic processes, whereas ClC-2 has a more diffuse membrane localisation in astrocytes. These disease observations suggest that GlialCAM is a straightforward chaperone for MLC1, but that its relation with ClC-2 is more complex.
The growing group of known disorders affecting brain ion and water homoeostasis are typically relatively mild compared with other brain disorders, both in mice (Bosl et al., 2001; Blanz et al., 2007; Edwards et al., 2010; Menichella et al., 2006) and human beings (van der Knaap et al., 1995 Knaap et al., & 2010 Lopez-Hernandez et al., 2011; Paulson et al., 2002) . The importance of the volume regulation process in the brain is emphasised by the observation that it does not rely on just one protein or one pathway. Mutations in one protein only lead to partial and sometimes transient dysfunction. It is important to note that intramyelinic oedema can be reversible.
Patients with megalencephalic leukoencephalopathy with subcortical cysts, caused by dominant GLIALCAM mutations, improve or recover spontaneously (van der Knaap et al., 2010; Lopez-Hernandez et al., 2011) . In most patients with a GJB1 mutation, the white matter disease is transient (Paulson et al., 2002) . If means are found to target components of the ion and water homoeostatic pathways, myelin oedema might be successfully combated.
The exons and intron-exon junctions of CLCN2 (accession number NG_016422.1)
were amplified and analyzed in these three adult patients, as described (SaintMartin et al., 2009 ). In the four selected patients with pediatric-onset disease, the exons and intron-exon junctions of CLCN2 were also sequenced, as described . Primer sets were designed to amplify exons for the longest transcript variant (accession number NM_004366.4) with Primer3 (http://frodo.wi.mit.edu/primer3/). They are listed in Table S8 . In those pediatric patients in whom no mutations were found or only one, CLCN2 mRNA was isolated from lymphoblasts and reverse-transcribed. CLCN2 cDNA was amplified in four overlapping fragments, which were sequenced using primers listed in Table S6. In the fourth patient, who had the X-linked disease the exons and intron-exon junctions of GJB1 (accession number NG_008357.1) were amplified and analyzed (primers listed in Table S8 ).
Mutation interpretation was assessed using Alamut2.1 (Interactive Biosoftware), shown in Table S7 . The CLCN2 and GJB1 mutation nomenclature is based on the cDNA reference sequences (NM_004366.4 and NM_000166.5 respectively), according to HGVS recommendations (www.hgvs.org/mutnomen).
Functional studies CLCN2 mRNA was quantified in available fibroblasts of two adult patients with CLCN2 mutations. Half of the cells were pretreated overnight with 10 µg/ml emetin to inhibit nonsense-mediated decay (NMD). Total RNA was isolated using the Qiagen RNeasy Mini kit (Invitrogen). First-strand synthesis was performed with 1 µg of total RNA using the SuperScript III First-Strand Kit (Invitrogen). Quantification was carried out using the Qiagen QuantiTect primer assays for CLCN2. PPIA and GAPDH were used as control genes. Each sample was run in triplicate on a Lightcycler-480 apparatus (Roche). Forty-five two-step cycles (30 s at 95°C and 30 s at 60°C) were performed. Analysis was performed using qbase Plus software (Biogazelle). 
Western blot analyses of endogenous ClC-2 in human brain tissue
To study ClC-2 expression, three ClC-2 antibodies were used: GTX113403
(GeneTex), SC-20122 (Santa Cruz) , and HPA24108 (Sigma). The GTX113403 and SC-20122 antibodies were both raised against the N-terminal part of ClC-2, whereas the HPA24108 antibody was raised against the C-terminal domain. To validate whether these anti-ClC-2 antibodies specifically detect ClC-2 in human brain samples, we performed several control experiments. First, HEK293 cells were transfected with the ClC-2-V5-His6 expression plasmid 3 using PEI. 5 Mock transfections were performed in parallel with pBlueScript. Lysates were prepared two days post-transfection as described (van Berge et al., 2013) . Equal amounts of protein were applied to 11% SDS-PAGE without prior boiling, because boiling severely diminished ClC-2 detection with all tested antibodies (data not shown). The samples were subsequently transferred to Immobilon-P membrane (Millipore) overnight. Total protein loading was measured in-gel and on-blot with 2,2,2-trichloroethanol (TCE) that labels all tryptophans in the proteins (Ladner et al., 2004) . TCE imaging was performed with Bio-Rad Image Lab software.
Membranes were blocked in 5% non-fat milk in PBS-0.1% Tween and incubated overnight at 4˚C with primary antibody (1:1000 for GTX113403; 1:500 for SC-20122, 1:1000 for HPA24108 and 1:10000 for anti-v5). Subsequently, membranes were incubated with an HRP-conjugated secondary antibody (1:5000, Westburg) and further developed using the SuperSignal West Femto chemiluminescencebased detection kit (Pierce). Images were obtained with a Li-Cor Oddysey imager (Westburg) using the Image Studio software package.
We performed Western blot analyses with the same set of anti-ClC-2 antibodies on brain lysates prepared from two of the control individuals also investigated in fluorescent immunohistochemistry. Equal amounts of protein (~100 μg per well, as determined by Bradford analysis) were applied to 4%-12% gradient gels without prior boiling (NuPAGE system, Invitrogen). After transfer, membranes were handled as described above. To increase the sensitivity of the assay, the blots were incubated with a goat anti-rabbit IgG secondary antibody (1 hr, 4˚C) and subsequently with an HRP-conjugated anti-goat IgG antibody (1 hr, 4˚C).
We also performed immunocytochemistry on the transfected HEK293 cells with the GTX113403 anti-ClC-2 antibody (1:200). The signal was detected with the AF488-conjugated anti-rabbit IgG antibody (Molecular Probes, 1:400).
Immunohistochemistry and electron microscopy
To study the expression of ClC-2, MLC1 and GlialCAM, tissue samples from the posterior limb of the internal capsule, frontal white matter, frontal cortex and ependymal lining were obtained at autopsy from 9 unrelated control subjects aged 1 to 75 years (7 males, 2 females), who succumbed to heart disease (lymphocytic myocarditis or acute myocardial infarction) or extra-cerebral tumor (gastric or bladder carcinoma). None of the subjects had neurological symptoms. Routine neuropathologic examination, including gross examination of the brain on cut and review of Hematoxylin and Eosin-stained tissue sections from multiple brain areas, was normal in all cases.
For light-microscopy purposes, 8-μm-thick frozen tissue sections were mounted on glass slides and fixed in 2% PFA, subsequently permeabilized with 0.1% saponin, blocked in 5% normal donkey serum and incubated with primary antibodies for 24 hours at 4°C. Immunohistochemistry was performed using antibodies against the following epitopes: glial fibrillary acidic protein (GFAP, Millipore, 1:1000); ClC-2 (GTX113403, 1:200; SC-20122, 1:20; HPA24108, 1:20) ; GlialCAM (R&D, 1:100); MLC1 (kind gift of Dr. R. Estévez, University of Barcelona, Spain, 1:100); oligodendrocyte transcription factor-2 (olig2, Millipore, 1:400); platelet endothelial cell adhesion molecule-1 (PECAM1/CD31, Dako, 1:50); neuronal nuclei (NeuN, Sigma, 1:500); phosphorylated neurofilaments (SMI31, Developmental Studies Hybridoma Bank, 1:1000); and non-phosphorylated neurofilament H (SMI32, Developmental Studies Hybridoma Bank, 1:1000). SMI31 and SMI32 antibodies were always applied simultaneously. In each experiment negative controls were included by omitting the primary antibody to verify the specificity of the immunohistochemical labeling. Specifically for the GTX113403 antibody, we included an isotype control rabbit IgG (SC-2027, Santa Cruz, 1:200) . Furthermore, we performed a blocking experiment with this antibody. In brief, the protein (aa 27-303 of ClC-2; GTX113403-PEP_SAMP, GeneTex) used to raise the GTX113403 antibody was pre-incubated with GTX113403 in a 100-fold molar excess for 2 hours at 4˚C whilst rotating. A control reaction was included in which the antigen was omitted.
After staining with secondary antibodies (Alexa 488-, 568-, and 594-tagged, Molecular Probes, 1:400), sections were counterstained with DAPI (Molecular Probes, 10 ng/ml) and photographed using a Leica DM6000B microscope (Leica Microsystems BV, Rijswijk, The Netherlands).
For electron microscopy (EM) purposes, tissue sections were fixed in 4% PFA, cryoprotected in 12.5% and 25% sucrose and frozen. Thirty to forty-μm-thick frozen sections were incubated for 96 hours with antibodies against ClC-2, GlialCAM, or MLC1, and then rinsed before being incubated in a PowerVisionPoly-HRP-Goat supplemented with 1% in potassium ferricyanide in sodium cacodylate buffer 0.1 M (pH 7.4). The material was then dehydrated and embedded in epoxy resin.
Ultrathin sections, longitudinal to the cortico-spinal tract, were examined and photographed with a FEI Technai 12 electron microscope.
All pictures were acquired as TIFF files. The images were optimized for brightness and contrast using Photoshop, version 7.0 (Abode systems, San Jose, CA). Number of genes common to ≥ 2 patients 14 8 24
Supplementary
Number of genes common to the 3 patients 5 5 11* Number of genes common to the 3 patients considering only variants absent from exomes of patients with other diseases**
(CLCN2)
* List of the 11 genes containing homozygous or at least two heterozygous, possibly deleterious variants common to the 3 adult patients: CLCN2, EXOC6B, MPV17, MUC4, SENP3, SLC30A10, TAS2R43, TMPRSS13, ZNF717 and ZNF880. ** Most variants in the EXOC6B, MPV17, MUC4, SENP3, SLC30A10, TAS2R43, TMPRSS13, ZNF717 and ZNF880 genes were identical in all three adult patients and were also present in exome data from individuals with other diseases analyzed at the same time (n=7). MUC4 and ZNF717 harboured multiple variants in all affected individuals and controls. 
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